Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 11—November 2007

Research

Human Salmonella and Concurrent Decreased Susceptibility to Quinolones and Extended-Spectrum Cephalosporins

Jean M. Whichard*Comments to Author , Kathryn Gay*1, Jennifer E. Stevenson*2, Kevin J. Joyce*, Kara L. Cooper*, Michael Omondi*, Felicita Medalla*, George A. Jacoby†, and Timothy J. Barrett*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Lahey Clinic, Burlington, Massachusetts, USA;

Main Article

Table 1

NARMS non-Typhi Salmonella serotypes with decreased susceptibility to quinolones and extended-spectrum cephalosporins, United States, 1996–2004*

Year No. that met MIC criteria/total tested (%) Serotype
Senftenberg Typhimurium Newport Enteritidis Other (no.)
1996 0/1,324 (0)
1997 1/1,301 (0.08) 1
1998 1/1,460 (0.07) 1
1999 1/1,497 (0.07) 1
2000 4/1,377 (0.29) 2 1 1
2001 4/1,419 (0.28) 2 1 Haifa (1)
2002 5/2,008 (0.25) 1 2 1 Mbandaka (1)
2003 4/1,864 (0.21) 2 1 Agona (1)
2004
7/1,793 (0.39)
3
1
1

Saintpaul (1),
Uganda (1)
Total 27/14,043 (0.19) 11 6 3 2 5

*NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofloxacin and >2 μg/mL for ceftiofur or >2 μg/mL for ceftriaxone.

Main Article

1Current affiliation: Banfield, The Pet Hospital, Philadelphia, Pennsylvania, USA

2Current affiliation: Washington State University, Pullman, Washington, USA

TOP